Overview

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Status:
Recruiting
Trial end date:
2030-06-01
Target enrollment:
Participant gender:
Summary
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Birmingham
Treatments:
Cyclophosphamide
Dactinomycin
Doxorubicin
Ifosfamide
Irinotecan
Temozolomide
Vincristine
Vinorelbine